GLP-1 Medications Beyond Weight Loss
What the Evidence Actually Shows Across the Body (and What It Does Not)
Current as of June 2026
GLP-1 receptor agonists are not new. The first, exenatide, was approved for type 2 diabetes in 2005, engineered from a compound discovered in the venom of the Gila monster. Liraglutide followed in 2010 and semaglutide in 2017. For most of that stretch these were respected but unremarkable diabetes drugs, prescribed quietly and rarely discussed outside endocrinology.
What changed was potency. The newer agents lowered blood sugar and produced weight loss far beyond anything the early versions could manage, and once semaglutide was approved for obesity in 2021 and the dual agonist tirzepatide arrived soon after, demand exploded. Spending on semaglutide for obesity alone rose from under 600 million dollars in 2021 to roughly 7 billion by 2023. Greater efficacy, new obesity approvals, intense media and celebrity attention, and a steady stream of positive trial data turned a twenty-year-old drug class into one of the most consequential stories in medicine almost overnight.
And weight, it turns out, is only part of that story. In a series of large randomized trials, these medicines have shown effects on the heart, kidneys, liver, lungs, brain and even patterns of addiction, several of which now carry their own regulatory approvals. Just as importantly, a few of their most hyped possibilities have failed when tested rigorously.
This resource is meant as a current, plain-language map of that evidence for clinicians and curious readers alike, written as of June 2026. The guiding principle throughout is simple. Where the evidence comes from randomized controlled trials, it is described with confidence. Where it comes from observational data, it is clearly labeled as a signal rather than proof. And where the honest answer is that we do not yet know, that is said plainly. From a lifestyle-medicine perspective, none of what follows replaces the foundations of sleep, nutrition, movement, stress and connection. These medications are best understood as powerful tools that work alongside those foundations, not substitutes for them.
GLP-1 Medications Beyond Weight Loss: Evidence Snapshot
Current as of June 2026. Study names link to the source.
| Benefit Area | What the Evidence Shows | Key Study (Year) | Evidence Level |
|---|---|---|---|
| Established: backed by randomized controlled trials | |||
| Cardiovascular disease | 20% fewer heart attacks, strokes, and cardiovascular deaths | SELECT (2023) | Strong (RCT) |
| Cardiovascular (oral pill) | Same protection extended to oral semaglutide | SOUL (2025) | Strong (RCT) |
| Longevity / survival | About 12% lower risk of death from any cause | Mortality meta-analysis (2025) | Strong |
| Chronic kidney disease | 24% fewer major kidney events; trial stopped early for benefit | FLOW (2024) | Strong (RCT) |
| Heart failure (HFpEF) | Better symptoms, exercise capacity, and less inflammation | STEP-HFpEF (2023) | Strong (RCT) |
| Obstructive sleep apnea | Large drop in breathing interruptions; FDA-approved 2024 | SURMOUNT-OSA (2024) | Strong (RCT) |
| Fatty liver disease (MASH) | Resolves MASH and improves scarring; FDA-approved 2025 | ESSENCE (2025) | Strong (RCT) |
| Peripheral artery disease | Longer, less painful walking distance | STRIDE (2025) | Strong (RCT) |
| Knee osteoarthritis pain | Less knee pain and better physical function | STEP 9 (2024) | Strong (RCT) |
| Emerging: promising but mostly observational, not yet proven | |||
| Stroke prevention | Roughly 15 to 16% fewer strokes | CVOT meta-analyses | Emerging |
| Atrial fibrillation | Roughly 13 to 18% fewer AF events | Meta-analysis (2024) | Emerging |
| Dementia prevention | 40 to 70% lower first Alzheimer's diagnosis (in diabetes) | Real-world cohort (2024) | Emerging |
| Alcohol use disorder | Less heavy drinking; about 50% lower AUD risk | Lancet RCT (2026) + cohorts | Emerging |
| Opioid use / overdose | Fewer overdoses and less opioid reliance | Cohorts (2025) | Emerging |
| Cancer risk | 17% lower overall obesity-related cancer risk | Cohort (2025) | Emerging |
| Depression / anxiety | Less worsening of symptoms (data are mixed) | National cohort (2026) | Emerging |
| PCOS | Better ovulation, cycles, and androgen levels | Reviews (2026) | Emerging |
| Psoriasis / hidradenitis | Improved skin disease and fewer related surgeries | Reviews & cohorts | Emerging |
| Bone health | Generally lower fracture risk | Meta-analyses (2025) | Emerging |
| Fibromyalgia | Less pain, fatigue, and opioid use | Cohort (2025) | Emerging |
| Migraine | Fewer acute-care visits and abortive-medication needs | Neurology cohort (2026) | Emerging |
| Intracranial hypertension | Lower pressure and fewer headache days | Exenatide RCT (2023) | Emerging (small RCT) |
| Smoking / nicotine | Mixed: one RCT positive, one negative | Exenatide pilot (2021) | Mixed |
The heart and circulation
The most consequential discovery is cardiovascular. In the SELECT trial of more than 17,000 adults who had heart disease and obesity but not diabetes, semaglutide reduced major cardiovascular events, meaning cardiovascular death, heart attack and stroke, by about 20 percent. Crucially, the benefit did not depend on how much weight a person lost, which suggests the drug protects the cardiovascular system through more than slimming alone. The SOUL trial later extended a similar cardiovascular benefit to the oral form of semaglutide in high-risk diabetes.
Around this central finding sit several supporting signals. Pooled analyses of cardiovascular trials suggest GLP-1 therapy is associated with roughly 15 to 16 percent fewer strokes, and meta-analyses link the class to fewer episodes of atrial fibrillation. In peripheral artery disease, the STRIDE trial showed that semaglutide improved how far people could walk before leg pain stopped them, along with their quality of life. The stroke and atrial-fibrillation data are largely observational or pooled and should be read as supportive rather than definitive, but the direction is consistent and encouraging.
Living longer, and surviving illness
Because cardiovascular and metabolic disease drive so much premature death, it is not surprising that the survival data have followed.
A large meta-analysis of nearly 100,000 patients found that GLP-1 receptor agonists were associated with a meaningful reduction in death from any cause, rated as high-certainty evidence.
One of the more striking details came from a prespecified analysis of SELECT: during the pandemic, people taking semaglutide were less likely to die of COVID-19, even though they were not less likely to catch it, hinting at a benefit in surviving serious illness rather than avoiding infection.
The kidneys
Kidney protection is now among the best-established non-weight benefits. The FLOW trial enrolled people with type 2 diabetes and chronic kidney disease and was stopped early because the benefit was so clear. Semaglutide reduced major kidney events, cardiovascular events and death by about 24 percent. For a field with relatively few therapies that slow the march toward dialysis, this was a landmark result.
Heart failure with preserved ejection fraction
Heart failure with preserved ejection fraction, the kind tightly linked to obesity, has long frustrated cardiologists because so little helps. In the STEP-HFpEF program, semaglutide improved symptoms, physical limitation and exercise capacity, and reduced inflammation, in patients with and without diabetes. These are the outcomes patients feel day to day, which makes the result especially meaningful.
Sleep apnea
In late 2024, tirzepatide became the first medication approved specifically for obstructive sleep apnea in adults with obesity, on the strength of the SURMOUNT-OSA trials. It cut the number of breathing interruptions per hour substantially and improved blood pressure and inflammatory markers. For patients who cannot tolerate CPAP, this opened a genuinely new avenue.
The liver
Fatty liver disease, now called metabolic dysfunction-associated steatohepatitis or MASH, has emerged as a major GLP-1 target. The phase 3 ESSENCE trial showed that semaglutide resolved MASH and improved liver scarring far more often than placebo, supporting a 2025 approval for the condition. The dual-agonist tirzepatide showed similar promise in the phase 2 SYNERGY-NASH trial, resolving MASH in a majority of patients, though as a phase 2 study it awaits confirmation.
The brain and mind: the most nuanced chapter of GLP-1s
Here the story is genuinely two-sided.
On the encouraging side, a real-world study of roughly a million people with diabetes found that semaglutide was associated with a 40 to 70 percent lower risk of a first Alzheimer's diagnosis compared with other diabetes drugs.
Yet when semaglutide was tested as a treatment for people who already had early Alzheimer's, the large EVOKE and EVOKE+ trials found no slowing of decline. The reasonable reading is that these drugs may help prevent dementia in people with metabolic risk, while doing little once the disease is established. Prevention and treatment are not the same thing.
Parkinson's disease tells a parallel cautionary tale. An early phase 2 trial of exenatide suggested a slowing of motor decline, and a phase 2 trial of lixisenatide later pointed the same way. But the larger phase 3 exenatide trial did not confirm a clinical benefit. The laboratory rationale remains strong, but the human evidence is, for now, unresolved.
On mood, a large Swedish national cohort found that people with existing depression and anxiety had less worsening of those conditions while taking semaglutide. This is reassuring, but other databases have produced mixed psychiatric signals, so the mental-health picture should be described as broadly reassuring yet not fully settled.
Addiction and the reward system
GLP-1 receptors sit in the brain's reward circuitry, and the leading expert reviews propose that these drugs dampen the dopamine signaling that drives craving. The human evidence is strongest for alcohol.
A randomized trial in the Lancet found that semaglutide reduced heavy-drinking days versus placebo, an earlier randomized trial in JAMA Psychiatry reduced craving and some drinking outcomes, and a real-world cohort of more than 80,000 people linked semaglutide to a roughly 50 percent lower risk of developing or relapsing into alcohol use disorder. Even the trial that missed its main target, an exenatide study, showed reduced drinking in the subgroup with obesity and quieter brain responses to alcohol cues.
For nicotine, the evidence is mixed and instructive. A pilot randomized trial of exenatide added to a nicotine patch nearly doubled quit rates, yet a larger randomized trial of dulaglutide found no improvement in abstinence at all, though it did blunt the usual post-quit weight gain.
Observational data also link GLP-1 use to fewer opioid overdoses and lower rates of cannabis use disorder. For stimulants such as cocaine, small human studies have so far been negative, and dedicated trials are only now underway. The fair summary is that alcohol is the most promising target, nicotine is genuinely mixed, and the rest remains early.
Other emerging benefits of GLP-1s
Several more areas are worth watching, all on observational footing. GLP-1 use has been associated with a lower overall risk of obesity-related cancers. In polycystic ovary syndrome, the drugs improve weight, insulin sensitivity, cycle regularity and ovulation, largely through metabolic improvement.
Dermatology has seen encouraging reports in psoriasis and hidradenitis suppurativa, and despite worries that rapid weight loss might weaken bone, the fracture data so far lean reassuring. There are also early reports of reduced binge-eating episodes, which should be discussed carefully given the importance of not encouraging disordered eating. Each of these deserves hedged language until randomized data arrive.
What the GLP-1 evidence does not yet fully support
Despite striking laboratory findings, GLP-1 drugs have no confirmed human benefit in neuropathic pain outside of weight and metabolic effects. Widely shared reports that these medications curb gambling, compulsive shopping or other behavioral addictions are, at this point, anecdotal rather than trial-tested.
Effects on male testosterone and erectile function are real in some studies and contradicted in others. And for stimulant and cannabis use disorders, the human evidence is not yet there. None of these should be presented to patients as established benefits.
GLP-1 safety and the honest risk picture
Every therapy that does this much carries trade-offs. The most common are gastrointestinal: nausea, vomiting, diarrhea and constipation, usually early and dose-related. Beyond those, two specific signals deserve naming because patients are asking.
The first is a rare optic-nerve stroke called non-arteritic anterior ischemic optic neuropathy, which large cohort studies have associated with semaglutide at a higher relative risk, though the absolute risk remains low. The second is a transient worsening of diabetic retinopathy when blood sugar falls quickly, which tends to stabilize over time and is being studied in a dedicated trial. Standard cautions also include pancreatitis, gallbladder disease, loss of muscle along with fat, and rare liver decompensation after very rapid weight loss in people with cirrhosis.
A brief note on GLP-1 and pain
Pain deserves a short, measured mention because it is where hope currently outpaces proof. The strongest evidence is the STEP 9 trial, a randomized study in which semaglutide reduced knee osteoarthritis pain and improved function in people with obesity.
Beyond that, the data are observational: a large cohort suggested people with fibromyalgia reported less pain, less fatigue and lower opioid use, another linked GLP-1 use to less opioid reliance in chronic pancreatitis, a 2026 neurology cohort found fewer acute-care visits among people with chronic migraine, and a small randomized trial showed reduced intracranial pressure and headache days in idiopathic intracranial hypertension.
The likely common thread is reduced inflammation and mechanical load rather than a direct painkiller effect. It is a promising and actively reviewed area, but outside knee osteoarthritis it should be framed as emerging, not proven.
GLP-1 summary as of June 2026
As of June 2026, the GLP-1 receptor agonists have earned their place as far more than weight-loss drugs. Their benefits for the heart, kidneys, liver, sleep apnea and survival rest on solid randomized evidence. Their possibilities in addiction, dementia prevention, mental health and pain are real but still maturing.
From a lifestyle-medicine standpoint, the most useful framing is holistic. These drugs can lower the metabolic and inflammatory burden that drives so much chronic disease, which in turn can make the foundational work of nutrition, movement, sleep and stress management more achievable. Used that way, with clear eyes about both benefits and risks, they are among the most versatile tools modern medicine has produced.
This article is for general educational purposes and reflects the published evidence available as of June 2026. It is not medical advice and does not establish a physician-patient relationship. Treatment decisions, including whether a GLP-1 medication is appropriate, should be made with a qualified clinician who knows your individual history. Linked studies throughout point to the primary sources.
Curious about GLP-1? Contact our office today.